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Abstract
We undertook an epidemiological survey of the annual incidence of pertussis reported from
2000 to 2013 in ten Central and Eastern European countries to ascertain whether increased
pertussis reports in some countries share common underlying drivers or whether there are
specific features in each country. The annual incidence of pertussis in the participating
countries was obtained from relevant government institutions and/or national surveillance
systems. We reviewed the changes in the pertussis incidence rates in each country to
explore differences and/or similarities between countries in relation to pertussis surveil-
lance; case definitions for detection and confirmation of pertussis; incidence and number of
cases of pertussis by year, overall and by age group; population by year, overall and by age
group; pertussis immunization schedule and coverage, and switch from whole-cell pertussis
vaccines (wP) to acellular pertussis vaccines (aP). There was heterogeneity in the reported
annual incidence rates and trends observed across countries. Reported pertussis incidence
rates varied considerably, ranging from 0.01 to 96 per 100,000 population, with the highest
rates generally reported in Estonia and the lowest in Hungary and Serbia. The greatest bur-
den appears for the most part in infants (<1 year) in Bulgaria, Hungary, Latvia, Romania,
and Serbia, but not in the other participating countries where the burden may have shifted to
older children, though surveillance of adults may be inappropriate. There was no consistent
pattern associated with the switch from wP to aP vaccines on reported pertussis incidence
rates. The heterogeneity in reported data may be related to a number of factors including
surveillance system characteristics or capabilities, different case definitions, type of pertus-
sis confirmation tests used, public awareness of the disease, as well as real differences in
the magnitude of the disease, or a combination of these factors. Our study highlights the
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Introduction
Pertussis (whooping cough) is a common, highly contagious and potentially serious acute
respiratory disease that continues to be a major public health concern worldwide. The disease,
mainly caused by Bordetella pertussis (B. pertussis), is transmitted to susceptible hosts directly
via airborne respiratory aerosol droplets ejected from infected individuals while coughing [1].
The introduction of childhood vaccination in the industrialized world during the 1950s and
1960s led to a>90% reduction in the incidence and mortality of pertussis in those regions [2].
However, the number of reported pertussis cases has gradually increased in recent years. This
resurgence of pertussis cases has been observed since the 1980s in a number of countries with
high vaccine coverage rates in Europe and elsewhere, but this has by no means been a ubiqui-
tous trend [3, 4].
In Europe, there is substantial variation in the reported incidence of pertussis between coun-
tries in any given year [5–9]—in 2012, the overall pertussis case rate was 10.9 cases per 100,000
population, with the highest rate reported in Norway (85.2 per 100,000) and the lowest with no
reported cases was Malta [8]. Moreover, The Netherlands reported the highest total number of
pertussis cases (N = 12,868), accounting for about 30% of the total reported to the European
surveillance system by member states. Comparisons between countries are limited by differ-
ences in laboratory procedures, completeness of reporting, and differences in awareness of
reporting of the disease.
The apparent resurgence of pertussis in some countries since the introduction of routine
childhood vaccination appears to have altered the dynamics of the disease with a trend towards
increased reports in older children, adolescents and adults [2, 5, 9–12], as well as an increase by
an average of 1.3 years in the period between epidemics [13]. The reasons for the changes in
disease dynamics are not well-understood [11, 12, 14]. However, acquired immunity following
infection and vaccination wanes after 4–20 years and 4–12 years, respectively [15], and as such,
epidemic cycles may be perpetuated by the continued transmission of pertussis among adoles-
cents and adults. In addition, it has been suggested that the increased number of pertussis cases
reported in adolescents and adults could have been due, in part, to the use of more sensitive
detection methods and increased media awareness [4, 5, 11, 12, 14]. A number of other hypoth-
eses have also been proposed including: antigenic divergence from vaccine strains; changes in
vaccine composition or schedule (lower efficacy of acellular pertussis [aP] vaccines relative to
whole cell pertussis [wP] vaccines or lower efficacy of pertussis vaccine associated with low
coverage of the reinforcing dose between 12 and 24 months); tendency of acellular vaccines to
induce Th2 rather than Th1 responses; population changes in immune profiles due to waning
immunity and/or rates of natural boosting [4, 16, 17]. As such, due to the inherent complexities
of pertussis disease dynamics, there is no widely accepted biological mechanism(s) to explain
the current epidemiology of pertussis.
An overview of the changing incidence trends in a number of countries may help ascertain
whether increased pertussis reports in some countries share common underlying drivers or
whether there are specific features in each country. Here we report the results of an analysis of
pertussis incidence in ten Central and Eastern European countries, based on information
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collected through an epidemiological survey. Understanding the underlying drivers of the
changing pertussis epidemiology over time may help guide national immunization
recommendations.
Materials and Methods
This descriptive analysis of pertussis surveillance data pertains to information collected from
2000 to 2013 in ten Central and Eastern European countries: Bulgaria, the Czech Republic,
Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Serbia, and Slovakia. The current study
was undertaken by an informal group of pertussis experts from Central and Eastern Europe
who meet annually to discuss issues related to pertussis, and as such, the countries chosen cor-
respond to the experts’ countries of origin. The analysis aimed to provide insights into the
changing incidence of pertussis over time in a given country, and between countries.
Data sources
Data were collated from relevant government institutions and national surveillance systems by
investigators in their respective countries using a structured survey [18–31]. The survey
focused on: the methods of pertussis surveillance (passive or active); case definition for pertus-
sis (clinical case definition, laboratory confirmation protocols and methods); incidence and
number of cases of pertussis by year, overall and by age group; population by year, overall and
by age group; deaths due to pertussis; pertussis immunization schedule, modifications during
the study period, and coverage (S1 and S2 Tables). Other validated sources or publications
were also used where available to complete any missing information. No imputations were per-
formed for missing data that could not be located.
Data analysis
Data were entered into a Microsoft Excel spreadsheet and the annual incidence of pertussis per
100,000 population calculated by dividing the numbers of cases notified by population esti-
mates obtained from national sources (for Lithuania [32], Latvia [24] and Romania [The
National Institute of Statistics]) or directly from reported incidence rates from national surveil-
lance systems. Descriptive statistics (medians, quartiles and interquartile range) were used to
summarize the pertussis incidence rate over time, overall and by age-group. We assessed the
changes in the pertussis incidence rates in each country, and the differences and similarities
between countries in relation to a number of variables known or suspected to have an effect on
pertussis incidence including vaccination program and surveillance system characteristics.
Vaccination program variables included vaccine schedule, vaccine coverage and type of vaccine
(wP or aP, vaccine switch). Surveillance system characteristics included type of surveillance
(aggregate vs. case based reporting), targeted population (general population or part of the
population, pediatric or sentinels network), clinical case definitions (European Centre for Dis-
ease Prevention and Control, World Health Organization or other), and methods and proto-
cols for confirmation tests (culture, PCR, serology, other).
Finally, we appraised the relationship between the changing trends in reported annual per-
tussis incidence rates and the switch from wP to aP vaccination using the approach first devel-
oped by Hill [33]. Hill outlined a systematic approach to infer causation from statistical
associations observed in epidemiologic data based on nine criteria: temporality, strength, con-
sistency, specificity, dose-effect, plausibility, coherence, experiment and analogy. This
approach defines and describes conditions that must be satisfied to pass from an observed asso-
ciation to the acceptability of a causal relationship. This framework for causal inference
emerged in the 1950s and 1960s, following the international debate about the causal role of fat
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consumption on cardiac death rates, and later about the causal role of smoking in the occur-
rence of lung cancer. The "Hill Criteria" are considered more appropriate for analyzing obser-
vational data than tests of significance, especially when considering the impact of public health
interventions [33–35]. The viewpoints or guidelines used to evaluate evidence have not
changed since 1965 despite an increasing interest in causation and causal inference that has
mainly evolved on conceptual issues required for estimation of causal inference. Currently, the
nine viewpoints have been classified in two groups by the majority of epidemiologists [34]:
• one group, pooling 5 viewpoints (strength of association, consistency, specificity, temporal-
ity, biological gradient), summarizes data produced by the epidemiological studies (observa-
tional or experimental);
• the other group, pooling 4 viewpoints (plausibility, coherence, experiment, and analogy),
summarizes data produced by non-epidemiologic studies and supporting causal hypothesis.
Results
Vaccine schedule, coverage and exposure
Infants in 9 of the ten countries received a 3-dose primary series before seven months of age,
with a reinforcing dose between 12 and 36 months throughout the review period (Table 1). In
Slovakia, infants continuously received the primary series with a 2+1 schedule. At the begin-
ning of the review period, immunization started at 2 months (4 countries) or 3 months (6
countries), but two of them (Lithuania, Hungary) subsequently lowered the starting age from 3
to 2 months during the review period. Vaccination coverage with 4 doses (including the rein-
forcing dose of a 3+1 schedule) was90% in all countries (excluding Lithuania and Slovakia)
between 2000 and 2013, except Romania in 2009, 2011 and 2013 where the coverage was 82%,
89% and 88%, respectively. Coverage rates for 3 doses were also90% throughout the study
period in Lithuania (i.e., after dose 3 of a 3+1 schedule) and Slovakia (with a 2+1 schedule).
At the start of the review period, Hungary, Slovakia, the Czech Republic and Romania had a
preschool booster from about age 3 to 6 years, with Bulgaria, Estonia, Latvia, Lithuania and
Poland introducing a preschool booster during the study period (Table 1). Serbia is the only
country considered that does not have a preschool booster. Between 2006 and 2010, Estonia,
Hungary, the Czech Republic and Slovakia introduced additional boosters for older children
and adolescent.
All countries, except Poland and Serbia, switched to aP during the study period, with one or
two countries switching each calendar year from 2005 to 2010. In six countries, all doses were
switched from wP to aP simultaneously, while Bulgaria introduced aP for the pre-school
booster dose in 2008 and for the primary series in 2010, and Slovakia introduced aP for pri-
mary series in 2007/2008 and for the pre-school booster in 2009. National immunization pro-
grams in Poland and Serbia are based on wP, but aP vaccines have been available on private
market since 1999 and 2004, respectively, and in 2013 approximately 60% and 40% of infants
in these two countries received aP vaccines (Aneta Nitsch-Osuch and Vladimir Petrović, per-
sonal communications).
Surveillance network organization, clinical case definition and
confirmation tests
Surveillance for pertussis is passive in all countries, with some differences in surveillance sys-
tem characteristics, as well as clinical and laboratory diagnostic criteria (Table 2). In most
countries, the clinical case definition used are those provided by the World Health
Incidence of Pertussis in Central/Eastern Europe
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Table 1. Pertussis vaccination schedules by country.
Country Time period Primary series Reinforcing/Booster doses Coverage1
Toddlers Pre-school age Adolescence (min–max)
Bulgaria From 1992 to 2007 wP♦ 2, 3, 4 months wP♦ 2 years 89.7–94.0%
From 2008 to 2009 wP♦ 2, 3, 4 months aP >16 months aP 6 years 93.2–93.7%




Until 2006 wP□ 3, 4, 5 months wP□ 18–20
months
wP□ 4–5 years 99.6–99.6%
From 1 January 2007 to 14
February 2009
aP 3, 4, 5 months aP 18 months aP 5–6 years 92.8–99.3%
Since 15 February 2009 aP 3, 4, 5 months aP 18 months aP 5–6 years aP 10 years 92.1–98.0%
Estonia From 2000 to 2007 wP□ 3, 4.5, 6 months wP□ 2 years 91.7–95.8%
Since 2008 aP 3, 4.5, 6 months aP 2 years aP 6–7 years aP 15–16
years
96.0–96.7%
Hungary Before 2006 wP♦ 3, 4, 5 months wP♦ 3 years wP♦ 6 years 99.9–100%
Since 2006 aP 2, 3, 4 months aP 18 months aP 6 years aP 11 years 99.6–99.9%
Latvia From 1958 to 2004 wP□ 2, 4, 6 months wP□ 12–15
months
89.7–94.7%
From 2005 to 2009 aP 2, 4, 6 months aP 12–15
months
92.3–98.1%
Since 2010 aP 2, 4, 6 months aP 12–15
months
aP 7 years 90.0–97.9%
Lithuania From 1961 to 2003 wP□ 3, 4.5, 6 months wP□ 18 months 92.8–94.8%
From 2004 to 2006 wP□ 2, 4, 6 months wP□ 18 months 93.9–94.0%
Since 2007 aP 2, 4, 6 months aP 18 months aP 6–7 years§ 92.8–97.4%
Poland From 1960 to 2002 wP□ 2, 3, 5 months wP□ 16–18
months
94.7–94.8%
Since 2003# wP□ 2, 3, 5 months wP□ 16–18
months
aP 6 years‡ 94.7–96.0%
Romania From 1961 to September 2008 wP♦ 2, 4, 6 months wP♦ 12 months wP♦ 30–35
months
95.3–99.0%
From 1 October 2008 to March
2009
aP 2, 4, 6 months aP 13–15
months
aP 4 years 81.7–95.3%
Since 1 April 2009 aP 2, 4, 6 months aP 12 months aP 4 years 81.7–93.8%
Serbia Since 1960† wP♦ 2, 3.5, 5 months wP♦ 1–2 years 93.1–97.6%
Slovakia From 2000 to 2006 wP□ 3–4, 5–6, 11–12
months
wP□ 3 years wP□ 6 years 98.5–99.4%
From 2007 to 2008 aP 3–4, 5–6, 11–12
months
wP□ 3 years wP□ 6 years 99.3–99.4%
In 2009 aP 3–4, 5–6, 11–12
months
aP 6 years 99.2%
(2009)
Since 2010 aP 3–4, 5–6, 11–12
months
aP 6 years aP 13 years 96.8–99.1%
aP, acellular pertussis vaccine (all aP used in the participating countries were produced by an international manufacturer); wP, whole-cell pertussis
vaccine (□ wP produced by an international manufacturer and ♦ wP produced by local manufacturer)
1 Coverage with 4 doses (including reinforcing dose) between 2000–2013 unless otherwise specified. Coverage data for 4 doses (including reinforcing
dose) not available for Bulgaria in 2010–2012, for The Czech Republic in 2000–2003 and 2011–2012, and for Serbia in 2000–2004. Data for Estonia
includes coverage up to age 10 years. Data for Lithuania and Slovakia are after dose 3 of a 3+1 schedule and 2+1 schedule, respectively.
# No formal switch from wP in Poland, but aP widely available in private market
† No formal switch from wP in Serbia, but aP widely available in private market
‡ aP booster introduced for 16-year-olds in 2015
§ aP booster introduced for 15–16-year-olds in 2016
doi:10.1371/journal.pone.0155949.t001
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Table 2. Surveillance system, clinical and laboratory criteria used by country.




Bulgaria Passive; Mandatory notification;
Population-based surveillance; Aggregate
reporting
WHO criteria Yes# Until
2008
 1 change; Qualitative to quantitative








WHO criteria Yes Until
2000
 1 change; Qualitative to quantitative
test; kit change 2010
RT-PCR
since 2009
Estonia Passive; Mandatory notification;
Population-based surveillance; Case-
based reporting
WHO criteria Yes Rarely
used





Hungary Passive; Mandatory notification;
Population-based surveillance; Case-
based reporting
WHO/ECDC criteria Yes Until
2000
 1 change; Qualitative to quantitative
tests (hemagglutination to ELISA)
Since 2012
Latvia Passive; Mandatory notification;
Population-based surveillance; Case-
based reporting
ECDC criteria Yes Rarely
used
 1 change; Qualitative to quantitative
tests (PHT & WB to ELISA)
RT-PCR
since 2012
Lithuania Passive; Mandatory notification;
Population-based surveillance; Case-
based reporting
WHO/ECDC criteria Yes Until
2000
 1 change; Qualitative to quantitative
tests; Labsystem (2005–2010) &
Euroimmun since 2010
Since 2010‡
Poland Passive; Mandatory notification;
Population-based surveillance; Case-
based reporting
ECDC criteria Yes Rarely
used
 1 change; Qualitative to quantitative
tests; introduced kits such as Novatec
Rarely used




based on prolonged cough and
a high level of WBC
Yes Rarely
used
 1 change; No serology testing until
2008, then qualitative tests introduced
Sporadic
since 2012
Serbia Passive; Mandatory notification;
Population-based surveillance (sentinel
surveillance in one city [Novi Sad]); Case-
based reporting
GPI clinical Case Definition
used in 2012, in part, for sentinel
surveillance in one city (Novi
Sad)
Yes (since 2012) Not
used
 1 change; Clinical case definition
only until 2012, then quantitative tests
introduced (Euroimmun)
Since 2012
Slovakia Passive; Mandatory notification;
Population-based surveillance; Case-
based reporting
ECDC criteria Yes Until
2000
 1 change; Qualitative to quantitative
test
Since 2007
# Sofia and surrounding regions only
‡ PCR is available only at the university hospitals and national reference laboratory
ECDC, European Centre for Disease Prevention and Control; ELISA, enzyme-linked immunosorbent assay; GPI, Global Pertussis Initiative; PHT, passive
hemagglutination test; IF, immunofluorescence; RT-PCR, real-time polymerase chain reaction; WB, Western-blot; WHO, World Health Organization. The
ECDC clinical case definition is that stipulated by EU Commission (8 August 2012) as follows [37]: Any person with a cough lasting at least two weeks
and at least one of the following three symptoms: paroxysms of coughing; inspiratory "whooping", or post-tussive vomiting; or any person diagnosed as
pertussis by a physician; or apnoeic episodes in infants. Laboratory criteria includes at least one of the following three criteria: isolation of Bordetella
pertussis from a clinical specimen; detection of Bordetella pertussis nucleic acid in a clinical specimen; or Bordetella pertussis specific antibody response.
Serology results need to be interpreted according to the vaccination status. The WHO clinical case definition is as follows [36]: A case diagnosed as
pertussis by a physician or any person with a cough lasting at least two weeks with at least one of the following symptoms: paroxysms (i.e. fits) of
coughing; inspiratory whooping; post-tussive vomiting (i.e. vomiting immediately after coughing) without other apparent cause. Laboratory confirmation
includes: isolation of Bordetella pertussis; detection of genomic sequences by means of polymerase chain reaction; or positive paired serology. nucleic
acid. The GPI clinical case definition for surveillance purposes is dependent on the age of the person [38]. For those aged 0–3 months, this includes
cough and coryza or minimal fever plus: whoop, apnea, post-tussive emesis, cyanosis, seizure, pneumonia; or close exposure to an adolescent or adult
family member with a prolonged afebrile cough illness. For those aged 4 months to 9 years, this includes paroxysmal cough with no or minimal fever plus:
whoop, apnea, post-tussive emesis, seizure, worsening of symptoms at night, pneumonia; or close exposure to an adolescent or adult family member with
a prolonged afebrile cough illness. For those aged 10 years, this includes non-productive, paroxysmal cough 2 week duration without fever plus:
whoop, apnea, sweating episodes between paroxysms, post-tussive emesis, or worsening of symptoms at night. Laboratory confirmation in individual
suspected cases includes: detection by polymerase chain reaction or isolation of Bordetella pertussis in those aged 0–3 months, and increased white
blood cell count (20,000 leukocytes/ 10,000 lymphocytes) if the cough is <3 weeks duration. For those aged 4 month–9 year and those aged 10
years, a positive PT-IgG antibody response if  1 year after vaccination or detection of Bordetella pertussis by polymerase chain reaction if the cough is
<3 weeks duration confirm pertussis.
doi:10.1371/journal.pone.0155949.t002
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Organization (WHO) [36] or the EU Decision 2119/98/EC of the European Centre for Disease
Prevention and Control (ECDC) [37]. All countries changed their methods or protocols at
least once in the study period. For example, Serbia did not use a clinical case definition or con-
firmatory tests until 2012. Bulgaria has used qualitative confirmation tests since 2000 and PCR
was introduced in 2007 in the Sofia area only.
The majority of the countries notified pertussis cases based on clinical case definitions and
confirmatory tests with qualitative serology or culture only before 2005. However, qualitative
serology tests have since been gradually replaced with more sensitive and specific quantitative
serology tests. Detection of B. pertussis nucleic acid by polymerase chain reaction (PCR),
including real-time (RT)-PCR, was introduced between 2003 and 2012. By 2012, nearly all the
countries used PCR and/or serological ELISA tests (in house or commercial kits) to confirm
the majority of cases [39, 40].
Epidemiological changes
Intracountry changes. Bulgaria: The annual reported pertussis incidence ranged from 0.5
to 4.4 per 100, 000 population (Fig 1a). The introduction of the aP preschool booster vaccina-
tion in 2008 and the switch from wP to aP vaccines for the primary and toddler vaccinations in
2010 occurred at a time when the year-on-year reported incidence of pertussis had been gener-
ally decreasing. The introduction of PCR in 2007 (in the Sofia area) and the evolution of the
serology tests from 2006 to 2009 (Table 2), moving from passive hemagglutination test, immu-
nofluorescence and culture to PCR and more quantitative serological ELISA tests, also appear
to coincide with a decreasing trend in the incidence of reported pertussis. The overall age-
group trend in pertussis incidence rates (data available between 2006 and 2013 only) is sugges-
tive of a decrease in reported cases over time across all age groups.
Czech Republic: The annual reported pertussis incidence ranged from 1.2 to 11.7 per 100,000
population (Fig 1b). The overall trend was suggestive of a gradual underlying increased rate in
pertussis notifications during the study period. The switch to aP for the primary series, for the
reinforcing dose in the second year of life, and for the preschool booster in 2007 was followed by a
sharp increase in the reported incidence of pertussis. However, there was a reduction in the two
years following the introduction of the aP adolescent booster vaccination (at 10–11 years of age)
in 2009 before the incidence rate started to increase again. New serological assay kits and RT-PCR
were introduced for the diagnosis of pertussis around 2010 (Table 2), but these changes do not to
appear to have affected the underlying trend in the incidence of reported pertussis. Since 2008,
adolescents (10–19 year age group) have had the highest reported incidence of pertussis.
Estonia: Estonia was the country with the highest reported incidence of pertussis cases
among the ten participating countries, with annual incidence rates that ranged from 4.1 to 96.9
per 100,000 population (Fig 1c). The switch to aP vaccines and the concomitant introduction
of a preschool and an adolescent booster in 2008 was associated with an increase in the
reported incidence of pertussis—however, the reported pertussis incidence had started to grad-
ually increase two years earlier and continued to do so for another two years after the introduc-
tion of aP vaccines (peaking at 96.9 per 100,000). No temporal association with vaccines switch
and the introduction of boosters was observed. For most of the study period, pertussis was con-
firmed using qualitative serological tests, before quantitative ELISA tests were introduced in
2010/2011. Incidentally, the highest incidence of pertussis was reported 2010 but this returned
to similar levels as before in 2011. In general, the trends in the reported incidence of pertussis
were similar across all age groups, but tended to be lowest in infants.
Hungary: Hungary, along with Serbia (see below), had the lowest reported annual incidence
of pertussis among the ten countries: incidence rates ranged from 0.01 to 0.5 per 100,000
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Fig 1. Pertussis incidence in the ten participating Central and Eastern European countries, 2000–2013. aP: acellular pertussis vaccine
combined with diphtheria and tetanus toxoids. wP; whole cell pertussis vaccine combined with diphtheria and tetanus toxoids. Data not
available by age group for Lithuania.
doi:10.1371/journal.pone.0155949.g001
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population (Fig 1d). The switch to aP vaccines for the primary series of vaccination and for
toddlers, and the concomitant introduction of a preschool and an adolescent booster (at age 11
years) with aP vaccines in 2006 was not associated with an immediate decrease in the reported
incidence of pertussis. There was a change in the methods used to diagnose pertussis in 2008,
moving from passive hemagglutination tests to quantitative ELISA tests and PCR (Table 2).
These changes in diagnostic methods were followed by reduced incidence of pertussis reported
in the subsequent years. The incidence of pertussis was highest in infants. There were too few
cases reported or data were missing for the other age groups to observe any meaningful trends.
Latvia: Approximately ten-fold decrease in the reported annual pertussis incidence rate was
noted between 2000 and 2011, before a dramatic increase in 2012 (Fig 1e). Over the period, the
annual incidence of reported pertussis cases ranged from 0.4 to 13 cases per 100,000 popula-
tion. The switch to aP vaccines for the primary vaccination series and for the reinforcing dose
at 12–15 months of age in 2005 did not appear to modify the underlying decreasing trend in
incidence of reported pertussis cases. The introduction of a preschool booster (at 7 years of
age) in 2010 was followed two years later by an increase in reported cases. The incidence of per-
tussis was highest in infants throughout the study period.
Lithuania: The annual reported pertussis incidence ranged from 0.01 to 6.96 per 100,000
population (Fig 1f). In the seven years prior to the switch to aP vaccines for the primary series
of vaccination and for the reinforcing dose at 18 months of age, and concomitant introduction
of a preschool booster (at 6–7 years of age) in 2007, the average incidence of pertussis ranged
from 0.01 to 0.5 per 100,000 population. The switch to aP vaccines was accompanied by an
increase in reported pertussis incidence that peaked in 2009, and subsequently greater fluctua-
tion in the reported rates than were seen in the earlier years of the study. The laboratory meth-
ods used to diagnose pertussis changed to quantitative ELISA tests and included PCR around
2010 (Table 2). It is not clear how these changes in laboratory methodology affected pertussis
reporting rates. Data on the incidence of pertussis by age group was not available.
Poland: The annual incidence of reported pertussis cases ranged from 3.3 to 12.2 per
100000 population (Fig 1g). The introduction of aP vaccines for the preschool booster (at 6
years of age) in 2003 did not appear to have modified the underlying trend in the fluctuating
incidence of reported cases. Poland is one of two countries (the other is Serbia, see below) that
did not switch the primary series of vaccination or reinforcing dose to aP during the study
period. The vast majority of notified pertussis cases were confirmed by serology and rarely by
PCR or culture up to 2012. It is not clear whether changes in laboratory diagnosis during that
time played a role in the reported incidence of pertussis, and in particular in the doubling of
the reported incidence of pertussis in 2012 compared to other years. The incidence of reported
pertussis tended to be highest in infants up until 2006, but since then, the highest rates have
consistently been reported in adolescents (10–14 years of age).
Romania: Between 2000 and 2008 (the year of switch to aP vaccines for the primary series of
vaccination, for the reinforcing dose, and for preschool booster), there was an underlying
reduction in incidence of reported pertussis cases from 2.2 to a minimum of 0.22 per 100,000
population (Fig 1h). Although there was reduction in reported pertussis cases in 2009 (the year
after switching to aP) to 0.5 per 100,000 population, this was not sustained with the incidence
returning to similar levels as before. PCR diagnosis of pertussis was introduced in 2012
(Table 1), but used only sporadically. Although the data are incomplete for the age groups
assessment, infants tended to have the highest rates reported where comparative data were
available.
Serbia: Like Hungary, Serbia had the lowest reported annual incidence of pertussis among
the ten countries, with incidence rates that ranged from 0.01 to 0.7 per 100,000 population (Fig
1i). Serbia (like Poland) did not switch the primary series of vaccination or toddler boosters to
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aP during the study period. It is possible that the introduction of quantitative ELISA tests and
RT-PCR for the diagnosis of pertussis in 2012 may have contributed to the higher rates of per-
tussis reported that year. The incidence of pertussis was highest in infants in the years where
age-group data were available.
Slovakia: The annual reported pertussis incidence ranged from 0.01 to 0.8 per 100,000 pop-
ulation in the years preceding the switch to aP vaccines for the primary series of vaccination in
2007 (Fig 1j). From 2008, an increase in the incidence was observed, but it was mainly in the
10–19 year age group vaccinated with wP. The incidence eventually peaked in 2010, the year of
introduction of an aP adolescent booster (at 13 years of age). The annual incidence of reported
pertussis declined in the subsequent year and appears to have stabilized at about 17 per
100,000 population in the later part of the study, a level that is much higher than reported ear-
lier. It is possible that the introduction of PCR for the diagnosis of pertussis in 2007 and quanti-
tative ELISA test from 2010 (Table 2) may have had a role in the increased incidence of
reported pertussis in the subsequent years. Interestingly, the year the adolescent booster was
introduced was also the year that the adolescent group (10–19 years) had the highest reported
incidence of pertussis. Subsequently, similar annual rates of pertussis have been reported in the
adolescent group and in infants.
Intercountry changes. The annual notification rates of pertussis and general trends
observed during the study in the ten participating countries are summarized in Fig 2—this fig-
ure displays the same time series data presented in Fig 1 in a boxplot of annual incidence rates
by country. There were wide disparities in the annual reported pertussis incidences across the
Fig 2. Boxplot of overall annual pertussis incidence rates between 2000 and 2013 for each of the ten
participating Central and Eastern European countries. Each boxplot represents the median (black line in box)
and the 25th and 75th percentile incidence rates (edges of the box). The whiskers represent 1.5 x inter-quartile
range. Outliers are represented as blue dots.
doi:10.1371/journal.pone.0155949.g002
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ten countries, ranging from 0.01 to 96.9 per 100,000 population. Estonia had the highest annual
incidence of reported cases. Overall, the reported pertussis incidence rates across countries
were highly heterogeneous (Fig 3). Moreover, except in 2012 with five countries experiencing
an incidence peak, we did not observe synchrony in the reported pertussis incidence rates
between countries during the study period.
There were 11 pertussis associated deaths reported across the ten countries during the study
period, most of which occurred in unimmunized infants (Table 3); the case fatality rate over the
study period ranged from 0.06 to 1.5 per 1000 cases in the six countries that reported deaths.
Hill criteria for causality
In this section, we briefly appraise the relationship between the switch from wP to aP vaccina-
tion and the changing trends in reported annual pertussis incidence rates using Hill’s criteria of
causality. The idea of these causality considerations is to provide a mechanism for inferring
causal association between two factors before it is possible to assume causality from multiple
information sources rather than a binary yes or no approach to causality [33, 34]:
• Temporal sequence—not supported. There was no temporal sequence observed in the switch
from wP to aP and reported pertussis incidence rates in all the eight countries that switched
to aP during the study period. Although it could be loosely argued there were increased per-
tussis incidence rates after the switch to aP in six countries, the time period between the
switch and the rising incidence of notified pertussis varied from four years before the switch
Fig 3. Boxplot of the overall annual incidence of pertussis reported across all participating countries for
each of the calendar years in the study period. Each boxplot represents the median (black line in box) and the
25th and 75th percentile incidence rates (edges of the box). The whiskers represent 1.5 x inter-quartile range.
Outliers are represented as blue dots.
doi:10.1371/journal.pone.0155949.g003
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to seven years after. In addition, similar fluctuating trends were also observed in two coun-
tries where wP was mainly used throughout the study period.
• Consistency—not supported. There was no consistent pattern observed in reported pertussis
incidence rates following the switch from wP to aP in the eight countries that switched to aP
during the study period. Epidemiologic trends of increased pertussis incidence rates follow-
ing widespread aP use reported from observational studies undertaken in Australia and the
USA have been proposed as evidence of a switch effect [41–45]. However, there are also
reports of increased pertussis incidence rates in countries that continue to rely on wP [46–
48]. In addition to observations from our analysis, this leads us to conclude that the evidence
of a switch effect is inconsistent.
• Strength of association—not supported. Due to the low consistency and the variable temporal
sequence, the strength of this association was difficult to estimate. Using the median value as
reference by country, in the six countries showing some sort of temporal sequence the highest
reported incidences after the switch corresponded to 1.2- to 10-fold increase in the overall
incidence. However, in the two countries (Bulgaria and Romania) where it could be argued
that there was no temporal sequence with the switch to aP, and in the two countries (Poland
and Serbia) that did not switch to aP on a national level, the variation of the notified overall
Table 3. Pertussis associated deaths in 10 Central and Eastern European countries (2000–2013).
Country Number of
deaths






4 2005 Newborn Male Unvaccinated Too young for vaccination.
2007 4
months
Female Unvaccinated Vaccination postponed because of acute respiratory illness (later
confirmed as the first signs of pertussis disease).
2008 4 weeks Female Unvaccinated Too young for vaccination.
2009 2
months
Female Unvaccinated Too young for vaccination.
Hungary 0
Estonia 1 2007 1 month Male Unvaccinated Family history: pertussis was diagnosed in mother and older brother
before infant.
Latvia 2 2012 1 month Female Unvaccinated Mother was not vaccinated during pregnancy. Cause of death: ARDS,
MODS, hyperleukocytosis, septic shock, right lower extremity necrosis,
left foot ischemia. Pertussis DNA positive.
2013 9
months
Female Unvaccinated Refusal of vaccination form signed by parents. Cause of death: brain
edema, pulmonary emphysema, atelectasis, pulmonary hemorrhage.
Pertussis DNA positive.
Lithuania 1 2012 5
months
Male Unvaccinated Child from a ‘natural life style believer’ family. No vaccination, no other
medical services. Child started coughing about a month before admission
to the hospital. No treatment at home except ‘natural medicines’. Seizures
progressed despite treatment: coma, bradycardia. Death after 32 hours of
treatment.
Poland 2 2005 5
months
Female Unvaccinated Premature delivery (32 weeks gestation). Reason for lack of vaccination:
neurological contraindications
2008 68 years Male Unvaccinated Cause of death: cardiopulmonary insufficiency
Romania 0
Serbia 0
Slovakia 1 2013 57 years Male Unknown Underlying chronic pulmonary disease and cor pulmonale
ARDS, acute respiratory distress syndrome; DNA, deoxyribonucleic acid; MODS, Multi organ dysfunction syndrome
doi:10.1371/journal.pone.0155949.t003
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incidences between median value and maximal values was similar with a range from 1.2- to
14-fold increase towards the end of the study period.
• Specificity—not supported. Exposure to aP was not universally linked to increased incidence
of pertussis. In each country, among the different age groups exposed to wP or aP, the varia-
tion of pertussis incidence was similar and not specific to age groups exposed to aP. In addi-
tion, the reports of increased incidence in countries where wP vaccines remain the standard
of care argue against the specificity of the association [46–48].
• Dose-effect response—not supported. The present review did not provide an opportunity to
assess this aspect of the association. The effect of the number of wP priming doses on the
possible association with pertussis incidence has been studied in the US and Australian set-
tings [42, 49]. However, whether there is a possible association remains controversial, since
potential confounding factors were identified in the database used for the US study [42] and
the association lacked statistical significance in the Australian analysis [49].
• Biologic plausibility—inconclusive. A number of plausible mechanisms to explain a possible
switch effect have been postulated and include faster waning of vaccine-induced immunity,
differential orientation of the immune response (Th1 and Th17 vs. Th2) and changes in char-
acteristics of circulating B. pertussis strains under selective pressure from vaccination [12].
However, these hypotheses have been based on studies, some of which suffered from limita-
tions related to statistical power, potential confounding or were conducted in animals with-
out human-study confirmation. In contrast, human epidemiologic modelling suggested
otherwise [50].
• Coherence—not supported. Although the effect of the switch from wP to aP for the primary
immunization series has been proposed as a cause for the resurgence of pertussis in some
countries, alternative hypotheses have also been put forward to explain the reported varia-
tions of pertussis incidence over time such as, improvement in surveillance methods [51],
changes in disease circulation patterns [52], suboptimal vaccination coverage [53], or change
of disease awareness [51, 54], leading to a broader consensus that the resurgence of pertussis
is likely the result of a multifactorial effect.
• Experimental evidence—inconclusive. Some of the randomized vaccine efficacy trials in the
1990s showed that wP vaccines had higher efficacy estimates than aP vaccines [11]. Experi-
mental data in baboons and mice have also suggested that the immunity elicited by wP vac-
cines better protects against colonization and transmission than immunity elicited by aP
vaccines [55, 56], and thus, may provide a rationale for pertussis resurgence. However, these
studies in animals were not statistically powered to confirm any difference between treatment
groups and it remains to be determined whether these observations are applicable to humans
[50].
• Analogy—not supported. We are unaware of similar effects with other vaccines, so this Hill
criterion is neither refuted nor supported.
In summary, the analysis of the possible causal association of the switch from wP to aP vac-
cine with a possible resurgence of pertussis using the Hill criteria has lead us to conclude that
the evidence from our study is not supportive of such a causal association. Expanding the evi-
dence review to additional published data provides some support, but with a more complex
picture of possible causes for pertussis resurgence, of which the contribution of the wP to aP
vaccine switch remains inconclusive. Finally, based on the evidence from the Australian or US
settings, any effect the switch between vaccines may have had on pertussis epidemiologic
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trends would likely be undetectable given that the period of switch to aP vaccine assessed in
our study was less than 10 years in most of the countries.
Discussion
This article provides a comprehensive analysis of the annual incidence of pertussis collected in
ten Central and Eastern European countries from 2000 to 2013. The epidemiological data col-
lected show that pertussis continues to be a relevant public-health concern despite high vacci-
nation coverage across these countries. There was heterogeneity in the reported annual
incidence rates and trends observed across countries. The greatest burden appears for the most
part in infants in Bulgaria, Hungary, Latvia, Romania, and Serbia, but not in the other partici-
pating countries where the burden may have shifted to older children, and adolescents. Similar
heterogeneity in pertussis incidence rates (including wide differences in rates between coun-
tries) and trends have been reported previously in five of the countries included in our study
[57], across Europe [6–8] and globally [4]. The heterogeneity in reported incidence rates may
be related to a number of factors including surveillance system characteristics or capabilities,
different case definitions, type of pertussis confirmation tests used, public awareness of the dis-
ease, compliance with reporting, as well as real differences in the magnitude of the disease, or a
combination of these factors.
There were very few pertussis-associated deaths reported during the study period; the case
fatality rate ranged from 0.06 to 1.5 per 1000 cases in those countries that reported deaths. This
low mortality rate is consistent with that published in a EUVAC.NET surveillance report for
the period 2003–2007; during that period there were 27 pertussis-associated deaths reported
across eight countries (including four countries participating in our study) resulting in a case
fatality rate ranging from 0.1–7.1 per 1000 cases in those countries [58]. The case fatality rates
reported in our study and by EUVAC are based on very few deaths and likely represent a gross
underestimation. In general, deaths due to pertussis are not well recognized.
Differential underreporting between countries are common problems with all surveillance
systems and may have contributed to the observed heterogeneity in the incidence of pertussis
reported. Under-detection in adolescents and adults may be a particular problem as the disease
may not be recognized—a prolonged cough illness might be the only clinical feature in this
population. Indeed, data was lacking for the incidence of pertussis reported in adults. The
extent of underreporting in the countries included in the current study is difficult to ascertain
but may be substantial for some. For example, a study at a single hospital in Bucharest, Roma-
nia, assessing the circulation of B. pertussis in the locality in 2012 identified 51 suspected cases
of which 32 (63%) were confirmed using culture, real-time PCR, and in house ELISA methods.
Of these cases, the hospital sent 46 samples to the National Reference Laboratory, whereas only
251 samples were referred by the whole country during that year. The number of cases con-
firmed by the hospital represented about half of the total (32/70) confirmed cases in the coun-
try, but these 32 cases were not entered into the national surveillance system, as they were
detected through a separate project [59]. Underreporting likely occurs even in countries with
high incidences of reported cases. Prospective studies assessing the incidence of pertussis in
adolescents and adults have reported values of 370 and 500 per 100,000, respectively [60, 61].
As such, it may be argued that the highest incidence rates in our study are closest to the real
incidence of pertussis. Moreover, in Estonia, a cross-sectional serosurvey of 9- to 14-year-olds
undertaken between April–August 2012 estimated the incidence of B. pertussis infection to be
6.3%, which was>60-fold higher than officially reported [62]. However, B. pertussis infection
is frequently asymptomatic and its incidence therefore is much higher than that of pertussis
disease [63]. A recent review of pertussis seroprevalence studies confirms the gross
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underestimation of pertussis incidence based on reported cases compared to findings from
seroprevalence studies [64].
During the study period, a number of changes in immunization schedules occurred which
may have played a part in the changing incidence of pertussis reported. These changes include:
earlier first dose immunization, later preschool administration, and preschool and adolescent
booster introduction. The changes in vaccine immunization schedules were generally intro-
duced to provide direct and indirect protection for infants who are too young to be fully immu-
nized from severe disease, and as such, would likely have affected the age-stratified disease
incidence. The introduction of the preschool and/or adolescent boosters have been suggested
to possibly reduce transmission from older siblings to young infants not or not fully vaccinated
[65, 66], but others have reported that this effect may be modest at best or not observed [67–
69]. In contrast, a modelling study has also suggested that increased vaccination of children
would cause a shift in age-specific incidence towards an increased number of cases reported in
teenagers and adults [70].
Eight of the ten countries in our study switched from wP to aP vaccines between 2005 and
2010, but two countries continued their national infant immunization programmes with wP
vaccine (Poland and Serbia). For the countries that switched to aP, three distinct time periods
can be identified: 1) before 2005 where all countries used wP; 2) between 2005 and 2010 where
a mixture of both wP and aP were in use, with differing exposure rates to wP and aP by age-
group within each country; and 3) after 2010 when all new birth cohorts were exposed to aP
vaccines. Since 2010, progressively, all children younger than 3 years should have been exposed
to aP (excluding Poland and Serbia). Over the survey period, all children older than 7 years
would have been exposed to wP at least for their primary series and reinforcing dose, and all
the population in Serbia and Poland would have been exposed to wP vaccines (although aP has
been available in the private market). With the current hypothesis of reduced effectiveness and
faster waning immunity with aP than wP vaccines, a switch effect would likely be observed in
children younger than 7 years based on differential priming effect of aP and wP in those chil-
dren who did not received a wP primary series. Latvia may have had a temporal association
with the switch from wP to aP, with an increased incidence in reported cases occurring 7 years
after the switch to aP for the primary series and reinforcing doses. However, in Latvia, as in
other countries, the increasing incidences were reported concomitantly in age groups exposed
to aP (mainly infants) and to wP (7–17 year olds). Our observations do not support a switch
effect from wP to aP during the study period, but it is possible that the time period since
switching in most countries in our study was too short to observe such an effect that has been
described more than 10 years after switching in the USA [71].
The wide variation in pertussis incidence reported between countries may also be related
to the difference in the procedures and laboratory methods used to confirm B. pertussis infec-
tion. This information was difficult to collect precisely and introduced a potential bias in our
analysis. The heterogeneity in methods used for the laboratory confirmation of pertussis
diagnosis among European countries has been previously highlighted as a limiting factor in
evaluation of the effects of different pertussis immunisation programmes across Europe [39,
40]. In each country, the confirmation tests used in routine practice have been modified at
least once over the study period. Recommendations for standardization and harmonisation
of serological tests and nucleic acid amplification tests for the diagnosis of B.pertussis infec-
tions in Europe have since been published [72, 73]. Moreover, nine of the ten countries in
our study (excluding Serbia) were involved in surveys and external quality assurance (EQA)
programs implemented in Europe since 2011 to standardize laboratory methodologies and
protocols to ensure accurate and consistent diagnosis of pertussis reported to national sur-
veillance systems [39, 40].
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These on-going initiatives may have influenced the incidence of notified pertussis cases
after 2011, and could explain, at least partially, the increase in cases reported in 2012 including
the two countries where most infants were exposed to wP throughout the study period.
Increased laboratory testing in suspected cases and the more widespread use of enhanced sensi-
tivity PCR diagnostic methods may have contributed to the increasing incidence of reported
cases of pertussis [3, 51]. For example, in Serbia, we observed an increase in the incidence of
reported pertussis in 2012, the year after starting confirmation of pertussis cases with serology
and PCR in the sentinel network. In addition, the increase in the reported incidence in Latvia
in 2012 occurred in parallel with the introduction of quantitative ELISA tests and RT-PCR in
2011/2012. It is also possible that increased physician awareness as a result of publicity sur-
rounding the on-going pertussis initiatives may have increased reporting rates. There are
examples of increased media attention or medical information campaigns drawing awareness
to pertussis resulting in increased reporting rates to national surveillance systems [74]. Greater
physicians awareness of pertussis has been suggested by the WHO SAGE pertussis working
group to have, in part, contributed to the increase in cases reported in recent years in the
majority of countries where such increases have been noted [3]. It is possible that physician
awareness may have changed during the survey period, however, it is difficult to assess aware-
ness of pertussis among reporting physicians and such studies are lacking.
The variation in incidence of pertussis infection with age is well-described and is one of the
main changes reported in the vaccine era with increasing incidence in infants, especially those
too young to be immunized or partially immunized, and in adolescents and adults population
in Europe [6] and in north America [12]. Of note, the majority of deaths reported in our study
were of infants who had either not been vaccinated or were too young to have received the full
series of primary vaccinations. Age can be also a confounding factor in assessing the relation-
ship between aP switch and incidence of pertussis due to the strong co-linearity between age
and type of vaccines in observational surveys investigating the effect of the switch from wP to
aP [75].
This review of the reported incidence of pertussis in ten Central and Eastern European
countries has several limitations. We did not attempt to document hospitalisations associated
with pertussis. In addition, we did not sufficiently document the changes in laboratory methods
for the diagnoses of pertussis over time and between countries to determine whether increased
laboratory testing and/or use of more sensitive methods may have influenced pertussis report-
ing rates particularly in more recent years. Although it is likely that increased physician aware-
ness may have contributed to the increased incidence of pertussis reported, this would have
been difficult to document. These two issues would have been sufficient to confound any
assessment of the role of vaccine related factors in the changing incidence of reported pertussis.
Nonetheless, our analysis provides a reasonable approach towards a greater understanding of
pertussis epidemiology at the global level.
Conclusions
The annual reported rates of pertussis and general trends observed during the study period
across the ten participating countries were heterogeneous, with wide disparities in the inci-
dences of reported cases. There was no clear cycle or obvious synchrony in reporting rates
using overall or infant incidence data across the countries, except during 2012 where it could
be argued that peak incidence rates were reported in five countries. There was no consistent
pattern associated with the switch from wP to aP vaccines on reported pertussis incidence
rates. The heterogeneity in reported data probably does not reflect significant true differences
in pertussis incidence but is rather related to a number of factors including surveillance system
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characteristics or capabilities, different case definitions, sensitivity of pertussis confirmation
tests used, awareness of the disease, as well as real differences in the magnitude of the disease,
or a combination of these factors. These data confirm the necessity to standardize pertussis sur-
veillance programs in Europe, especially for the detection and confirmation of pertussis cases
and to complete this approach with carefully-designed seroprevalence studies using the same
protocols and methodologies. This will allow for more reliable inter-country comparisons of
the magnitude of B. pertussis circulation and disease.
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